Paper41807809
A year in pharmacology: new drugs approved by the US food and drug administration in 2025.
Kayki-Mutlu G and 3 others. Naunyn Schmiedebergs Arch Pharmacol, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. A year in pharmacology: new drugs approved by the US food and drug administration in 2025. Papers, record 41807809. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41807809
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- A year in pharmacology: new drugs approved by the US food and drug administration in 2025.
- PubMed
Topics5
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Drug Approval | Major topic |
| United States | |
| Humans | |
| United States Food and Drug Administration | |
| Animals |
Source PubMed
References137
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36253825 | Long-term safety and efficacy of gene-corrected autologous keratinocyte grafts for recessive dystrophic epidermolysis bullosa. | Orphanet J Rare Dis | 2022 | https://conductscience.org/library/papers/36253825 | PubMed |
| 2 | 36951997 | A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022. | Naunyn Schmiedebergs Arch Pharmacol | 2023 | https://conductscience.org/library/papers/36951997 | PubMed |
| 3 | 40880034 | Linvoseltamab: First Approval. | Drugs | 2025 | https://conductscience.org/library/papers/40880034 | PubMed |
| 4 | 37959392 | A PRoliferation-Inducing Ligand (APRIL) in the Pathogenesis of Immunoglobulin A Nephropathy: A Review of the Evidence. | J Clin Med | 2023 | https://conductscience.org/library/papers/37959392 | PubMed |
| 5 | 40570869 | Prademagene zamikeracel for recessive dystrophic epidermolysis bullosa wounds (VIITAL): a two-centre, randomised, open-label, intrapatient-controlled phase 3 trial. | Lancet | 2025 | https://conductscience.org/library/papers/40570869 | PubMed |
| 6 | 40673861 | Donidalorsen Treatment of Hereditary Angioedema in Patients Previously on Long-Term Prophylaxis. | J Allergy Clin Immunol Pract | 2025 | https://conductscience.org/library/papers/40673861 | PubMed |
| 7 | 40540142 | Revakinagene Taroretcel: First Approval. | Mol Diagn Ther | 2025 | https://conductscience.org/library/papers/40540142 | PubMed |
| 8 | 38879802 | Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma. | J Clin Oncol | 2024 | https://conductscience.org/library/papers/38879802 | PubMed |
| 9 | 40261472 | Garadacimab: First Approval. | Drugs | 2025 | https://conductscience.org/library/papers/40261472 | PubMed |
| 10 | 41594098 | In Vitro Activity of Zoliflodacin Against Neisseria gonorrhoeae Isolates from Shanghai, China (2020-2023). | Antibiotics (Basel) | 2026 | https://conductscience.org/library/papers/41594098 | PubMed |
| 11 | 24914142 | Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. | Blood | 2014 | https://conductscience.org/library/papers/24914142 | PubMed |
| 12 | 40779124 | Nipocalimab: First Approval. | Drugs | 2025 | https://conductscience.org/library/papers/40779124 | PubMed |
| 13 | 41222831 | Taletrectinib: First Approval. | Drugs | 2026 | https://conductscience.org/library/papers/41222831 | PubMed |
| 14 | 40864501 | FDA Approval Summary: Datopotamab Deruxtecan-dlnk for Treatment of Patients with Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer. | Clin Cancer Res | 2025 | https://conductscience.org/library/papers/40864501 | PubMed |
| 15 | 37932009 | Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren's syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial. | Ann Rheum Dis | 2024 | https://conductscience.org/library/papers/37932009 | PubMed |
| 16 | 40222822 | Rilzabrutinib for the Treatment of Immune Thrombocytopenia. | Eur J Haematol | 2025 | https://conductscience.org/library/papers/40222822 | PubMed |
| 17 | 41212379 | Sunvozertinib: a Promising Oral EGFR Inhibitor Approved for NSCLC with EGFR Ex20ins Mutations. | Invest New Drugs | 2025 | https://conductscience.org/library/papers/41212379 | PubMed |
| 18 | 39947256 | Therapeutic PCSK9 targeting: Inside versus outside the hepatocyte? | Pharmacol Ther | 2025 | https://conductscience.org/library/papers/39947256 | PubMed |
| 19 | 40924012 | Efficacy and in vitro activity of gepotidacin against bacterial uropathogens, including subsets with molecularly characterized resistance mechanisms and genotypes/epidemiological clones, in females with uncomplicated urinary tract infections: results from two global, pivotal, phase 3 trials (EAGLE-2 and EAGLE-3). | Antimicrob Agents Chemother | 2025 | https://conductscience.org/library/papers/40924012 | PubMed |
| 20 | 37639462 | Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial. | Eur Heart J | 2023 | https://conductscience.org/library/papers/37639462 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41807809
GET https://conductscience.org/api/papers/v1/41807809/references?page=2